Setting new standards in cancer care
Providing Precision as a Service TM
Precision Molecular (PMI)’s mission is to translate the innovative research led by internationally recognized scientists and clinicians into life-saving cancer treatment. PMI is a clinical stage radiopharmaceutical company focusing on the development novel radiotherapeutic and imaging agents to target cancer cells with precision. We specialize in targeted alpha-particle therapy using Astatine-211 labeled radiopharmaceuticals.
Greater accuracy. Better outcomes.
Unlike anatomic imaging, such as magnetic resonance (MR) imaging and computed tomography (CT), molecular imaging measures biological processes with great precision and enhanced specificity.
Rapid innovation is at the core of what we do.
PMI has several radiopharmaceuticals in preclinical and clinical development aimed at tackling an array of imaging challenges and treatments for cancer.
January 26, 2022
Ionetix and Precision Molecular Inc. Announce Supply Agreement for Astatine-211
December 21, 2021
September 28, 2021
We’re taking on cancer with the brightest minds.
We’re a team of scientists, researchers, radiologists, and more, working together to change the way we approach cancer detection and treatment.
Get in touch with us.
704 Quince Orchard Road Suite 320
Gaithersburg, MD 20878
info@precisionmol.com
240.937.5880